Abstract
Enfuvirtide (Fuzeon; Trimeris/Roche), the first in a new class of anti-HIV drugs that inhibit the entry of the virus into cells, was approved by the US FDA in March 2003 for the treatment of HIV-1 infection in treatment-experienced patients. Is it likely to become a blockbuster?
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Extracellular secretion of a recombinant therapeutic peptide by Bacillus halodurans utilizing a modified flagellin type III secretion system
Microbial Cell Factories Open Access 04 August 2011
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Lalezari, J. P. et al. Enfuvirtide, an HIV-1 fusion inhibitor for drug-resistant HIV infection in North and South America. N. Engl. J. Med. (2003) Mar 13 (doi: 10.1056/NEJMoa035026)
De Clercq, E. Strategies in the design of antiviral drugs. Nature Rev. Drug Discov. 1, 13–25 (2002).
Wild, C. T. et al. Peptides corresponding to a predictive α-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl Acad. Sci. USA 91, 9770–9774 (1994).
Kilby, J. M. et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nature Med. 4, 1302–1307 (1998).
FDA Drug Approvals List [online] (cited 28 March 2003) <http://www.fda.gov/cder/foi/label/2003/021481lbl.pdf> (2003).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
LaBonte, J., Lebbos, J. & Kirkpatrick, P. Enfuvirtide. Nat Rev Drug Discov 2, 345–346 (2003). https://doi.org/10.1038/nrd1091
Issue Date:
DOI: https://doi.org/10.1038/nrd1091
This article is cited by
-
Mechanisms underlying HIV-associated cognitive impairment and emerging therapies for its management
Nature Reviews Neurology (2023)
-
Triazolyl Ru(II), Os(II), and Ir(III) complexes as potential HIV-1 inhibitors
BioMetals (2022)
-
CNS Neurotoxicity of Antiretrovirals
Journal of Neuroimmune Pharmacology (2021)
-
Extremophilic proteases as novel and efficient tools in short peptide synthesis
Journal of Industrial Microbiology and Biotechnology (2017)
-
Extracellular secretion of a recombinant therapeutic peptide by Bacillus halodurans utilizing a modified flagellin type III secretion system
Microbial Cell Factories (2011)